COMMUNIQUÉS West-GlobeNewswire

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
20/04/2026
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, [...]
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
20/04/2026
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
19/04/2026
Company announcement – No. 8 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April [...]
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
19/04/2026
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Fedora Pharmaceuticals Presentations at 2026 ESCMID Highlight Safety and Potent Bactericidal Activity of FPI-2119
19/04/2026
Potent antibacterial activity against Gram-negative community and hospital-acquired infections highlighted across eight posters and two presentationS EDMONTON, Alberta , April 19, 2026 (GLOBE NEWSWIRE) -- Fedora [...]
Herz P1 Smart Oximeter Claims Evaluated: Best Pulse Oxygen Monitor Device on the Market with Clinical-Grade Accuracy
19/04/2026
A 2026 informational report on the Herz P1 Smart Oximeter fingertip pulse oxygen monitor, covering the company's FDA 510(k) cleared positioning, ±2% SpO2 blood oxygen accuracy specifications, smart alarm alert features [...]
Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation
18/04/2026
A 2026 informational overview of Vigor Boost Gummies ingredient disclosures, proprietary blend structure, label-vs-marketing discrepancies, ForceVital male enhancement positioning, and what men should verify before [...]
SlimLeaf Claims Evaluated: The FitBurn Formula Using Slim Leaf Ingredients for Weight Loss
18/04/2026
A 2026 informational report on the SlimLeaf Akkermansia probiotic gut health formula, FitBurn weight management ingredient research, Slim Leaf supplement facts, CFU dosing context, pricing, and what consumers should [...]
MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy
18/04/2026
Federal action signals growing recognition of psychedelic therapies’ potential to address urgent mental health challenges, including PTSD, depression, and substance use disorders Expanding research must be paired with [...]
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
18/04/2026
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR’s Clinical Trials Mini [...]
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
18/04/2026
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability [...]
Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe
18/04/2026
ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe Première étude comparative de phase 4, randomisée, en double aveugle, [...]
VigoSurge Claims Evaluated: Analyzing the Ingredients' Benefits, Side Effects Risk and Customer Complaints
18/04/2026
A consumer information release covering what VigoSurge states about its 14-ingredient male health formula, including ingredient descriptions, side effects considerations, refund policy details, and commonly searched [...]
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
18/04/2026
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study [...]
VidaCalm Claims Evaluated: Analyzing the Formula's Ingredients, Side Effects Risk and User Complaints
18/04/2026
A 2026 structured overview of VidaCalm's 18-ingredient hearing support formula, ingredient research context, safety considerations, and what consumers searching for tinnitus relief should verify before purchasing Aurora [...]
Steel Flow Pro Claims Evaluated: Analyzing the Prostate Support Ingredients, Side Effects Risk and Hidden Complaints
18/04/2026
A 2026 consumer information release on Steel Flow Pro prostate support ingredients, Graminex flower pollen extract, saw palmetto, label disclosures, and what men should verify before ordering Largo, FL, April 17, 2026 ( [...]
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
17/04/2026
FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April 16, 2026, the Company [...]
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
17/04/2026
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/04/2026
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]

Pages